Acrivon Therapeutics

ACRVPhase 2

Boston, United Statesacrivon.com

Acrivon Therapeutics is pioneering a proteomics-based approach to precision oncology with its AP3 platform, which directly measures disease-driving protein activity to overcome the limitations of genomic biomarkers. The company has built a pipeline focused on DNA Damage Response and cell cycle targets, led by the Phase 2 candidate ACR-368, and is developing internally discovered compounds including ACR-2316 (dual WEE1/PKMYT1 inhibitor) and ACR-6840 (CDK11 inhibitor). With operations in Boston and Scandinavia, Acrivon aims to transform cancer treatment by accurately matching therapies to patients most likely to respond, addressing high unmet needs in prevalent solid tumors.

Market Cap

$259.7M

Focus

Small Molecules

ACRV · Stock Price

USD 8.238.41 (-50.54%)

Historical price data

AI Company Overview

Technology Platform

Acrivon Predictive Precision Proteomics (AP3) platform uses high-resolution mass spectrometry and automated tumor biopsy-imaging to develop OncoSignature companion diagnostics that match patients with optimal therapies based on proteomic profiling of disease-driving mechanisms.

Pipeline Snapshot

3 drugs in pipeline

Drug	Indication	Stage
ACR-368 + Gemcitabine	Endometrial Adenocarcinoma	Phase 2
Gemcitabine + ACR-368	Head and Neck Squamous Cell Carcinoma	Phase 2
ACR-2316	Specific Advanced Solid Tumors	Phase 1

Funding History

Total raised: $243M

IPO$80MUndisclosedFeb 15, 2024

Series B$100MPerceptive AdvisorsOct 15, 2022

Series A$63MRA Capital ManagementJun 15, 2021

Opportunities

The AP3 platform's broad applicability enables expansion into multiple cancer types and therapeutic areas, with potential for co-development partnerships around OncoSignature tests for accelerated approval pathways.

The growing recognition of proteomics' importance in precision medicine creates market timing advantages.

Risk Factors

Clinical validation of both the lead drug candidate and the novel proteomics-based companion diagnostic represents significant development risk.

The company faces competition from larger, better-funded players in both therapeutic and diagnostic spaces, and must successfully execute across two geographic locations.

Competitive Landscape

Acrivon competes with DNA Damage Response and cell cycle inhibitor developers like AstraZeneca and Merck, proteomics platform companies like Nautilus Biotechnology, and diagnostic giants like Roche. Its differentiation lies in the integrated development of therapeutics and companion diagnostics using proprietary proteomic profiling to address limitations of genomic biomarkers.